ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) and Avadel Pharmaceuticals (NASDAQ:AVDL – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability.
Risk & Volatility
ProQR Therapeutics has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500.
Earnings & Valuation
This table compares ProQR Therapeutics and Avadel Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProQR Therapeutics | $17.88 million | 10.00 | -$30.43 million | ($0.32) | -6.84 |
| Avadel Pharmaceuticals | $27.96 million | 31.02 | -$160.28 million | ($0.79) | -11.39 |
Insider & Institutional Ownership
32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 4.8% of Avadel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares ProQR Therapeutics and Avadel Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProQR Therapeutics | -134.31% | -71.58% | -19.70% |
| Avadel Pharmaceuticals | -52.53% | -93.34% | -44.77% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for ProQR Therapeutics and Avadel Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProQR Therapeutics | 0 | 0 | 5 | 1 | 3.17 |
| Avadel Pharmaceuticals | 0 | 0 | 8 | 0 | 3.00 |
ProQR Therapeutics currently has a consensus price target of $8.83, indicating a potential upside of 303.35%. Avadel Pharmaceuticals has a consensus price target of $19.88, indicating a potential upside of 120.83%. Given ProQR Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe ProQR Therapeutics is more favorable than Avadel Pharmaceuticals.
Summary
ProQR Therapeutics beats Avadel Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
About Avadel Pharmaceuticals
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
